BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced that eight abstracts have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC. Presentations will disclose new findings about its anti-cancer programs: ARRY-162, ARRY-543, AZD6244 (ARRY-886) and three emerging programs for RAF, Chk1 and mTor inhibition.
